Previous data show that the effects of clozapine on regional brain activity are different from those of other antipsychotic agents. It seemed of interest to study the brain activity patterns after treatment with clozapine, since this drug might correct basal deficits directly related to schizophrenia or instead induce changes that would in some way compensate distant abnormalities. In order to study the activity pattern resulting from clozapine treatment we have used FDG-PET and statistical parametric mapping (SPM) to explore the functional status of patients after chronic treatment with this drug, We compared their metabolic activity with normal controls and neuroleptic-naive (NN) patients, with the aim to identify if a reversion of pre-existing deficits or a induction of different changes was the result of clozapine administration. We compared metabolic patterns in 23 treatment-resistant (TR) patients after 6 months of treatment with clozapine, eighteen healthy subjects, and 17 NN schizophrenia patients. After treatment with clozapine, TR patients showed a clear hypofrontality and caudate hypometabolism in comparison with both the controls and NN patients, and also a lower thalamic activity than the healthy controls. In conclusion, our results support a preferential role for prefrontal regions and their subcortical connections in the mechanism of action of clozapine, resulting in a clearly hypofrontal state as compared to both controls and schizophrenia patients without previous treatment.
References
1
Andreasen NC.
PET and the [15O]H2O technique, Part 2: Choosing a significance threshold.
Am J Psychiatry.
1996;
153
6
2
Andreasen NC, Rezai K, Alliger R, Swayze VWd, Flaum M, Kirchner P, Cohen G, O’Leary DS.
Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Assessment with xenon 133 single-photon emission computed tomography and the Tower of London.
Arch Gen Psychiatry.
1992;
49
943-958
4
Bartlett EJ, Brodie JD, Simkowitz P, Dewey SL, Rusinek H, Wolf AP, Fowler JS, Volkow ND, Smith G, Wolkin A. et al .
Effects of haloperidol challenge on regional cerebral glucose utilization in normal human subjects.
Am J Psychiatry.
1994;
151
681-686
6
Cohen RM, Nordahl TE, Semple WE, Andreason P, Litman RE, Pickar D.
The brain metabolic patterns of clozapine- and fluphenazine- treated patients with schizophrenia during a continuous performance task.
Arch Gen Psychiatry.
1997;
54
481-486
8
Efron B, Tibshirani R.
Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy.
Statistical Science.
1986;
1
54-77
13
Gispert JD, Pascau J, Reig S, Martinez-Lazaro R, Molina V, Garcia-Barreno P, Desco M.
Influence of the normalization template on the outcome of statistical parametric mapping of PET scans.
Neuroimage.
2003;
19
601-612
14
Grobin AC, Deutch AY.
Dopaminergic regulation of extracellular gamma-aminobutyric acid levels in the prefrontal cortex of the rat.
J Pharmacol Exp Ther.
1998;
285
350-357
17
Holcomb HH, Cascella NG, Thaker GK, Medoff DR, Dannals RF, Tamminga CA.
Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol.
Am J Psychiatry.
1996;
153
41-49
18
Huntley GW, Vickers JC, Morrison JH.
Cellular and synaptic localization of NMDA and non-NMDA receptor subunits in neocortex: organizational features related to cortical circuitry, function and disease.
Trends Neurosci.
1994;
17
536-543
22
Meltzer HY, Bastani B, Ramirez L, Matsubara S.
Clozapine: new research on efficacy and mechanism of action.
Eur Arch Psychiatry Neurol Sci.
1989;
238
332-339
24
Miller DD, Andreasen NC, O'Leary DS, Watkins GL, Boles Ponto LL, Hichwa RD.
Comparison of the effects of risperidone and haloperidol on regional cerebral blood flow in schizophrenia.
Biol Psychiatry.
2001;
49
704-715
25
Moghaddam B, Bunney BS.
Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study.
J Neurochem.
1990;
54
1755-1760
26
Molina Rodriguez V, Montz Andree R, Perez Castejon MJ, Capdevila Garcia E, Carreras Delgado JL, Rubia Vila FJ.
SPECT study of regional cerebral perfusion in neuroleptic-resistant schizophrenic patients who responded or did not respond to clozapine.
Am J Psychiatry.
1996;
153
1343-1346
36 Talairach J, Tournoux P. Co-planar Stereotaxic Atlas of the Human Brain. Thieme Medical Stuttgart, New York 1988
37
Tauscher J, Hussain T, Agid O, Verhoeff NP, Wilson AA, Houle S, Remington G, Zipursky RB, Kapur S.
Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
Am J Psychiatry.
2004;
161
1620-1625
39
Volk DW, Pierri JN, Fritschy JM, Auh S, Sampson AR, Lewis DA.
Reciprocal alterations in pre- and postsynaptic inhibitory markers at chandelier cell inputs to pyramidal neurons in schizophrenia.
Cereb Cortex.
2002;
12
1063-1070
43
Zink M, Schmitt A, May B, Muller B, Braus DF, Henn FA.
Differential effects of long-term treatment with clozapine or haloperidol on GABA transporter expression.
Pharmacopsychiatry.
2004;
37
171-174
